Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761)
碩士 === 台北醫學院 === 藥學研究所 === 90 === The potential herb-drug interaction should be screened since the usage of herbal products became popular. Six bleeding cases have been reported with the use of Ginkgo biloba extract, and one was linked to concurrent use of warfarin. The objective of the s...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2002
|
Online Access: | http://ndltd.ncl.edu.tw/handle/15950063265395258419 |
id |
ndltd-TW-090TMC00551008 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-090TMC005510082016-06-24T04:14:58Z http://ndltd.ncl.edu.tw/handle/15950063265395258419 Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761) Warfarin與銀杏葉萃取物(EGb761)交互作用之評估 ChiaFeng Lai 賴佳楓 碩士 台北醫學院 藥學研究所 90 The potential herb-drug interaction should be screened since the usage of herbal products became popular. Six bleeding cases have been reported with the use of Ginkgo biloba extract, and one was linked to concurrent use of warfarin. The objective of the study was to evaluate the effect of EGb 761, a standardized Ginkgo biloba extract, on warfarin and coagulation function. To recognize the influence of EGb 761 on pharmacokinetics and pharmacodynamics of warfarin, changes in warfarin plasma concentration and prothrombin time (PT) after coadministration with EGb 761 were studied in a Sprague Dawley model. Clinical cases with concurrent use of two drugs were also retrospectively reviewed to evaluate the relationship between EGb 761 and international normalized ratio (INR). Changes of coagulation parameters, including platelet counts, INR, bleeding time, clotting time, was determinated in twelve healthy volunteers taking EGb 761 120 mg once daily for 28 days. A significant decrease in the area under plasma concentration-time curves (AUC) from 22.54±2.67 to 17.27±1.64 μg·hr/ml, was detected with coadministration of EGb 761 under a multiple dosing design (p=0.002). Similarly, maximal PT and area under the PT versus time curve were significantly reduced with EGb 761 treatment group (p=0.001). There was no significant change in INR after adding EGb 761 in 21 clinical cases (p=0.551). No clinically significant change in coagulation parameters was observed when finishing the regimen. No clinically significant influence of EGb 761 on warfarin was found on clinical cases and healthy volunteers. As the animal results of decreased pharmacokinetic and pharmacodynamic effects of warfarin, careful monitoring of PT was recommended with concurrent use of EGb 761 and warfarin. Chen, Chi-ming Chen, Hsiang-yin 陳繼明 陳香吟 2002 學位論文 ; thesis 122 zh-TW |
collection |
NDLTD |
language |
zh-TW |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 台北醫學院 === 藥學研究所 === 90 === The potential herb-drug interaction should be screened since the usage of herbal products became popular. Six bleeding cases have been reported with the use of Ginkgo biloba extract, and one was linked to concurrent use of warfarin. The objective of the study was to evaluate the effect of EGb 761, a standardized Ginkgo biloba extract, on warfarin and coagulation function. To recognize the influence of EGb 761 on pharmacokinetics and pharmacodynamics of warfarin, changes in warfarin plasma concentration and prothrombin time (PT) after coadministration with EGb 761 were studied in a Sprague Dawley model. Clinical cases with concurrent use of two drugs were also retrospectively reviewed to evaluate the relationship between EGb 761 and international normalized ratio (INR). Changes of coagulation parameters, including platelet counts, INR, bleeding time, clotting time, was determinated in twelve healthy volunteers taking EGb 761 120 mg once daily for 28 days. A significant decrease in the area under plasma concentration-time curves (AUC) from 22.54±2.67 to 17.27±1.64 μg·hr/ml, was detected with coadministration of EGb 761 under a multiple dosing design (p=0.002). Similarly, maximal PT and area under the PT versus time curve were significantly reduced with EGb 761 treatment group (p=0.001). There was no significant change in INR after adding EGb 761 in 21 clinical cases (p=0.551). No clinically significant change in coagulation parameters was observed when finishing the regimen. No clinically significant influence of EGb 761 on warfarin was found on clinical cases and healthy volunteers. As the animal results of decreased pharmacokinetic and pharmacodynamic effects of warfarin, careful monitoring of PT was recommended with concurrent use of EGb 761 and warfarin.
|
author2 |
Chen, Chi-ming |
author_facet |
Chen, Chi-ming ChiaFeng Lai 賴佳楓 |
author |
ChiaFeng Lai 賴佳楓 |
spellingShingle |
ChiaFeng Lai 賴佳楓 Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761) |
author_sort |
ChiaFeng Lai |
title |
Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761) |
title_short |
Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761) |
title_full |
Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761) |
title_fullStr |
Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761) |
title_full_unstemmed |
Evaluation of the Interaction between Warfarin and Ginkgo biloba extract (EGb 761) |
title_sort |
evaluation of the interaction between warfarin and ginkgo biloba extract (egb 761) |
publishDate |
2002 |
url |
http://ndltd.ncl.edu.tw/handle/15950063265395258419 |
work_keys_str_mv |
AT chiafenglai evaluationoftheinteractionbetweenwarfarinandginkgobilobaextractegb761 AT làijiāfēng evaluationoftheinteractionbetweenwarfarinandginkgobilobaextractegb761 AT chiafenglai warfarinyǔyínxìngyècuìqǔwùegb761jiāohùzuòyòngzhīpínggū AT làijiāfēng warfarinyǔyínxìngyècuìqǔwùegb761jiāohùzuòyòngzhīpínggū |
_version_ |
1718321407182503936 |